Sugi Predict

Sugi Predict / Targets / ERCC5

ERCC5

DNA excision repair protein ERCC-5 · P28715 · ERCC5 on Sugi Atlas →

19,481 patent compounds predicted against ERCC5, 13,756 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL292473 SCHEMBL292473 0.46 8/20
SCHEMBL440631 SCHEMBL440631 0.65 4/20
SCHEMBL441329 SCHEMBL441329 0.65 4/20
Silver Silver (SCHEMBL527868) 0.65 4/20
SCHEMBL383767 SCHEMBL383767 0.46 4/20
SCHEMBL115267 SCHEMBL115267 0.45 4/20
SCHEMBL636225 SCHEMBL636225 0.59 3/20
SCHEMBL70968 SCHEMBL70968 0.58 3/20
SCHEMBL419161 SCHEMBL419161 0.52 3/20
SCHEMBL271455 SCHEMBL271455 0.50 3/20
Phenylpyruvate Phenylpyruvate (SCHEMBL616906) 0.50 3/20
SCHEMBL92196 SCHEMBL92196 0.49 3/20
SCHEMBL419159 SCHEMBL419159 0.48 3/20
SCHEMBL419160 SCHEMBL419160 0.47 3/20
Dibenzoylmethane Dibenzoylmethane (SCHEMBL39582) 0.73 2/20
Dibenzoylmethane Dibenzoylmethane (SCHEMBL531257) 0.70 2/20
SCHEMBL599285 SCHEMBL599285 0.68 2/20
SCHEMBL269381 SCHEMBL269381 0.68 2/20
SCHEMBL98540 SCHEMBL98540 0.67 2/20
SCHEMBL441330 SCHEMBL441330 0.64 2/20

Clinical trials — most relevant to ERCC5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer PHASE3COMPLETED
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients PHASE3COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer PHASE2COMPLETED
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer PHASE2COMPLETED
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy PHASE2COMPLETED
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer PHASE2WITHDRAWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) PHASE2COMPLETED
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations PHASE2RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Olaparib in People With Malignant Mesothelioma PHASE2COMPLETED
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer PHASE2WITHDRAWN
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer PHASE2COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer PHASE1COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. nanUNKNOWN
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Family Study of Melanoma in Italy nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ERCC5 binder may also engage these)

ProteinNameSimilarity
P35689 — 0.996 P35689 →
P14629 — 0.996 P14629 →
Q9R207 — 0.986 Q9R207 →
Q7TN31 — 0.986 Q7TN31 →
Q8K2L8 — 0.985 Q8K2L8 →
Q501R9 — 0.983 Q501R9 →
Q5M954 — 0.983 Q5M954 →
O60934 — 0.983 O60934 →
Q76CY8 — 0.982 Q76CY8 →
Q9JIL9 — 0.982 Q9JIL9 →
Q5QJC2 — 0.981 Q5QJC2 →
Q8IW35 — 0.981 Q8IW35 →
Q6P7W5 — 0.981 Q6P7W5 →
Q62187 — 0.981 Q62187 →
Q69Z66 — 0.981 Q69Z66 →
TOR1AIP1 Torsin-1A-interacting protein 1 0.981 landscape →
Q53F19 — 0.981 Q53F19 →
Q8WYQ5 — 0.980 Q8WYQ5 →
Q5XIX3 — 0.980 Q5XIX3 →
Q8BMI4 — 0.980 Q8BMI4 →
Q5R6Z9 — 0.980 Q5R6Z9 →
Q99549 — 0.980 Q99549 →
Q5RCV3 — 0.980 Q5RCV3 →
Q9XSC3 — 0.980 Q9XSC3 →
F6RIX4 — 0.980 F6RIX4 →
Q6P2K3 — 0.979 Q6P2K3 →
Q9EQM6 — 0.979 Q9EQM6 →
Q9QXK2 — 0.979 Q9QXK2 →
Q6NVE8 — 0.979 Q6NVE8 →
Q8TEW8 — 0.979 Q8TEW8 →